ADMA Biologics, Inc. (NASDAQ:ADMA) concluded the trading on Wednesday, Oct 14 with a fall of -4.98% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $2.41 and 5Y monthly beta was reading 1.99 with its price kept floating in the range of $2.2700 and $2.4000 on the day. Company’s P/E ratio for the trailing 12 months is 0. Considering stock’s 52-week price range provides that ADMA hit a high price of $5.25 and saw its price falling to a low level of $1.45 during that period. Over a period of past 1-month, stock came losing -2.14% in its value.
With its current market valuation of $198.57 Million, ADMA Biologics, Inc. is set to declare its quarterly results on August 05, 2020. ADMA Stock’s Forward Dividend of 0 and its yield of 0 are making investors’ thoughts stronger that it could fall further before the company announces its earnings for the current quarter. Analysts are in estimates of -$0.2 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.87 for 2020 with estimates of that growing to -$0.52 in next year. These estimates are suggesting current year growth of -0.02% for EPS and -0.4% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $9.81 Million. They suggested that in the process company could generate revenue of as low as $9.27 Million which could climb up to $10.9 Million to hit a high. The average estimate is representing an increase of 35.8% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $39.32 Million in 2020, which will be +34% more from revenue generated by the company last year.
In contrast, when we review ADMA stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.
According to ratings assigned by 6 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; none of them are recommending ADMA Biologics, Inc. (ADMA) as a Hold, while 5 are in view that stock is a Buy. Recommendation by 1 analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas none of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Buy and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the ADMA stock which is currently positioned at 0. It further provides that stock’s current price level is -2.11% away from its 20-day simple moving average and is -10.61% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 42.65 while volatility remained at 4.8% over the past week which changes to 7.71% when measuring it over the past month. Beta is valued at 1.99, while measure of average true range or ATR is currently at 0.17. In predicting price targets of as low as $6 and as high as $12, analysts are in agreement on assigning the stock over the next 12 months average price target of $8.67. Stock’s current price level is 162.01% above from estimated low price target while it is 424.02% below the estimated high; and even if the ADMA’s share succeeded to reach the median price of $8.5, then the outlook of +271.18% could come to the excitement of the investors.
In comparing ADMA Biologics, Inc. (ADMA)’s stock with other industry players reveals that stock’s latest price change of -4.98% and that of -45.08% over the past 12 months is in competing position with that of Amgen Inc (AMGN) which saw its stock price fell by -0.71% in the recent trading and went through an increase of 16.12% in past 12-month trading. Industry’s another major player Bristol-Myers Squibb Company (BMY) has fell -0.21% down in latest trading session, but over the past year has faced a rise of 17.69%, while Gilead Sciences Inc (GILD) is also down -4.98% however its price remained floating in the red at -45.08% over the same period. ADMA Biologics, Inc. has a P/E ratio of 0 against that of Amgen Inc’s 19.42 while Bristol-Myers Squibb Company is showing 0 for the same. On the other hand, the S&P 500 Index was down -0.66% in the early deals while the Dow Jones Industrial was dealing lower at -0.58%.
Having a second look at ADMA Biologics, Inc. (NASDAQ:ADMA) provides that stock’s average daily trading volume for 3 months was 6.33 Million, while it dropped to 3.64 Million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock currently stood at 86.35 Million.
Data compiled by Thomson Reuters highlights that percentage of outstanding shares held by the insiders is 7.35% while it is 47.91% for the institutional holders. The figures also indicate that as of September 29, 2020, number of stock’s short shares was 13910000 which implies a short ratio of 3.94. This shows up a 16.11% of Short Interest in company’s outstanding shares on the day. In September the standing of shares short improved as it was 13.31 Million in the previous month. Drop of -42.75% by stock’s current price to its year-to-date value in today’s trading is likely to be increasing investors’ worries about the stock as it is hinting a further drop.